ArticleOphthalmic surgery, lasers & imaging retina
Efficacy of adalimumab for pediatric Vogt-Koyanagi-Harada syndrome.
Article in Ophthalmic surgery, lasers & imaging retina. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 37 citations in OpenAlex.
- Outcomes of Vogt-Koyanagi-Harada Disease: A Subanalysis From a Randomized Clinical Trial of Antimetabolite Therapies.American journal of ophthalmology · 2016Trial
- A complicated Vogt-Koyanagi-Harada presenting with bilateral papillitis in a 5-year-old- case report.Journal of ophthalmic inflammation and infection · 2025Article
- Efficacy and Safety of Adalimumab in Pediatric Non-infectious Non-anterior Uveitis: Real-life Experience From the International AIDA Network Uveitis Registry.Ophthalmology and therapy · 2023Article
- Vogt-Koyanagi-Harada Syndrome (VKHS): First Two Cases Reported in Pediatric Age Group in Oman.Case reports in pediatrics · 2023Article
- Mechanisms, Pathophysiology and Current Immunomodulatory/Immunosuppressive Therapy of Non-Infectious and/or Immune-Mediated Choroiditis.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Innovations in the diagnosis and management of uveitis: promising research to address unmet patient needs.Annals of eye science · 2022Article
- Adalimumab in Vogt-Koyanagi-Harada Disease Refractory to Conventional Therapy.Frontiers in medicine · 2021Article
- A Case of Recurrent Vogt-Koyanagi-Harada Disease Successfully Treated with Adalimumab in Young Female Adult Patient.Korean journal of ophthalmology : KJO · 2020Article
- Experience of using adalimumab in treating sight-threatening paediatric or adolescent Behcet's disease-related uveitis.Journal of ophthalmic inflammation and infection · 2019Article
- Long term treatment with infliximab in pediatric Vogt-Koyanagi-Harada disease.American journal of ophthalmology case reports · 2018Article
- An Update on Treatment of Pediatric Chronic Non-Infectious Uveitis.Current treatment options in rheumatology · 2017Article
- Vogt-Koyanagi-Harada syndrome - current perspectives.Clinical ophthalmology (Auckland, N.Z.) · 2016Review
- Adalimumab treatment for chronic recurrent Vogt-Koyanagi-Harada disease with sunset glow fundus: A multicenter study.Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological SocietyArticle
- The rescue effect of adalimumab in the treatment of refractory pediatric panuveitis complicated with steroid-induced glaucoma.Taiwan journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Pediatric Vogt-Koyanagi-Harada syndrome (VKH) is rare, with limited cases of corticosteroid-sparing immunosuppression use reported. A 15-year-old Hispanic girl was referred for bilateral intraocular inflammation. Her initial best corrected visual acuity (BCVA) was 20/30 in the right eye and 20/200 in the left eye, with granulomatous keratic precipitates, anterior chamber and vitreous cell, optic disc edema, and nummular depigmented chorioretinal lesions on examination consistent with VKH after an unrevealing work-up. Inflammation was recurrent despite oral prednisone and methotrexate. Adalimumab, a TNF-alpha inhibitor, led to rapid resolution of inflammation, successful dose reduction of prednisone and methotrexate, and final BCVA of 20/25 in the right eye and 20/40 in the left at 26-month follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.